Fitxers
Tipus de document
Part del llibreVersió
Versió publicadaData de publicació
Tots els drets reservats
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/32192
Is the 23-valent pneumococcal polysaccharide vaccine useful in preventing community-acquired pneumonia?
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Although bacteremic pneumococcal pneumonia is the most severe form of pneumonia, non-bacteremic forms are much more frequent. Laboratory methods for the diagnosis of nonbacteremic pneumococcal pneumonia have a low sensitivity and specificity, and therefore all-cause pneumonia has been proposed as a suitable outcome to evaluate vaccination effectiveness. This work reviews the epidemiology of community-acquired pneumonia (CAP) and evaluates the effectiveness of the 3-valent pneumococcal polysaccharide vaccine (PPV-23) in preventing CAP requiring hospitalization in people aged ≥65 years. We performed a case-control study in patients aged ≥65 years admitted through the emergency department who presented with clinical signs and symptoms compatible with pneumonia. We
included 489 cases and 1,467 controls and it was obtained a vaccine efectiveness of 23.6 (0.9-41.0). Our results suggest that PPV-23 vaccination is effective and reduces hospital admissions due to pneumonia in the elderly, strengthening the rationale for vaccination programmes in this age group.
Descripció
Podeu consultar el llibre complet a: http://hdl.handle.net/2445/32393
Matèries (anglès)
Citació
Col·leccions
Citació
IZQUIERDO, Conchita, SALLERAS I SANMARTÍ, Lluís and DOMÍNGUEZ GARCÍA, Àngela. Is the 23-valent pneumococcal polysaccharide vaccine useful in preventing community-acquired pneumonia?. Recent Advances in Pharmaceutical Sciences II. 2012. Vol. Editor: Diego Muñoz-Torrero, num. Diego Haro and Joan Vallès, pags. Chapter 5. [consulted: 19 of August of 2026]. Available at: https://hdl.handle.net/2445/32192